Dr. Dun Yang pursued his graduate study at Columbia University under the mentorship of Dr. James W. Erickson, received his postdoctoral training in cancer cell biology supervised by Dr. J. Michael Bishop at University of California, San Francisco (UCSF) and then worked as an associate specialist at the G. W. Hooper Research Foundation. Dr. Yang has conducted research for more than 20 years and has a track record of publication in PNAS, Nature Medicine, Nature Cell Biology, Current Biology and MCB. His published studies involve multiple research fields, such as animal cell division, apoptosis, autophagy, mouse tumor models, regulation of gene expression, RNAi and synthetic lethal therapies. His diverse research programs at UCSF were generously supported by the G. W. Hooper Research Foundation, the Susan G. Komen Foundation, and pharmaceutical companies such as Merck, Millennium and Exelixis.
Dr. Yang received Peter Sajovic Memorial Prize from Columbia University for excellence in biomedical research. At Columbia University, Dr. Yang developed a single-embryo transcription translation assay (SETTA) to dissect mechanisms underlying RNAi. His findings provided the first evidence that siRNA hydrolyzed from a sizeable double-stranded RNA mediates gene silencing in vivo. In addition, he worked on transcriptional regulation of the Sex-lethal (Sxl), a master regulatory gene of sex determination in Drosophila, revealed that the number, affinity, and position of sisB/Da-binding sites in the promoter of Sxl were critical for its female-specific activation, and proposed a reservoir model to explain dosage-sensitive regulation of Sxl. The findings have now been written into some college textbooks of genetics.
Together with Dr. Bishop at UCSF, Dr. Yang invented endoribonuclease–prepared siRNA (esiRNA) to silence gene expression in animal cells. The method has become a powerful screening tool for both functional genomic studies and identification of drug targets. Global patent protection of the practice held by UCSF and the use of it by many academic and industrial scientists in the literature testify to its utility. Under Dr. Bishop’s supervision, Dr. Yang also discovered a synthetic lethal interaction between overexpression of the Myc oncoprotein and disablement of chromosomal passenger protein complex (CPPC). This finding indicates that expression of Myc is a useful biomarker for the sensitivity of tumor cells to inhibition of the CPPC, suggests a therapeutic strategy for killing tumor cells that overexpress Myc, while sparing normal cells, and eliminates the liabilities of both the Myc oncoprotein as a therapeutic target and the mitotic inhibitors as therapeutic agents.
Contact Dr Dun Yang: Dun.Yang ‘at’ mbicr.org
Patents and selected publications:
Co-inventor with Dr. J. Michael Bishop: The aurora kinase inhibitor, VX-680, is a synthetic lethal agent for tumors that overexpress the MYC proto-oncogene (Invention report, UCSF case number SF2008-017).
Liu H, Radisky DC, Yang D, XuR, Radisky ES, Bissell MJ, Bishop JM.?MYC suppresses cancer metastasis by direct transcriptional silencing of v3 Integrin subunits.?Nature Cell Biology (2012) 14:567-74.
Yang D, Liu H, Goga A, Kim S, Yuneva M, and Bishop JM.?Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase.?PNAS (2010), 107:13836-41.
Goga A, Yang D, Aaron DT, Morgan DO, and Bishop JM.?Inhibition of Cdk1 as a potential therapy for tumor over-expressing MYC.?Nat Med?(2007), 13:820-827.
Yang?D, Buchholz F, Huang Z, Goga?A, Chen CY, Brodsky FM, and Bishop JM.?Short RNA duplexes produced by hydrolysis with Escherichia coli RNase III mediate effective RNA interference in mammalian cells.?PNAS (2002), 99:9942-7.